{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:08:18Z","timestamp":1790359698000,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cell.com","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.tips.2014.07.006","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T16:32:02Z","timestamp":1408033922000},"page":"493-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":319,"title":["Targeting Th17 cells in autoimmune diseases"],"prefix":"10.1016","volume":"35","author":[{"given":"Jianfei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Sundrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Skepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2014.07.006_bib0005","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.tips.2014.07.006_bib0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.tips.2014.07.006_bib0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2014.07.006_bib0020","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.tips.2014.07.006_bib0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.cell.2012.09.016","article-title":"A validated regulatory network for Th17 cell specification","volume":"151","author":"Ciofani","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.tips.2014.07.006_bib0030","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0035","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2014.07.006_bib0040","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nature06764","article-title":"Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome","volume":"452","author":"Milner","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.tips.2014.07.006_bib0045","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm0502-500","article-title":"Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis","volume":"8","author":"Lock","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2014.07.006_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.rdc.2010.02.006","article-title":"Targeting IL-17 and Th17 cells in rheumatoid arthritis","volume":"36","author":"Sarkar","year":"2010","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"10.1016\/j.tips.2014.07.006_bib0055","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF02684010","article-title":"Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction","volume":"51","author":"Lubberts","year":"2002","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.tips.2014.07.006_bib0060","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2014.07.006_bib0065","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.21342","article-title":"Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis","volume":"52","author":"Koenders","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2014.07.006_bib0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s11882-013-0361-0","article-title":"Clinical consequences of targeting IL-17 and TH17 in autoimmune and allergic disorders","volume":"13","author":"Robinson","year":"2013","journal-title":"Curr. Allergy Asthma Rep."},{"key":"10.1016\/j.tips.2014.07.006_bib0075","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/bjd.12110","article-title":"Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study","volume":"168","author":"Papp","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.tips.2014.07.006_bib0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2014.07.006_bib0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study","volume":"72","author":"Genovese","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tips.2014.07.006_bib0090","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2014.07.006_bib0095","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.tips.2014.07.006_bib0100","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1053\/j.gastro.2012.07.084","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohn's disease","volume":"143","author":"Targan","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2014.07.006_bib0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00281-009-0186-z","article-title":"Th17 cells in autoimmune demyelinating disease","volume":"32","author":"Segal","year":"2010","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.tips.2014.07.006_bib0305","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/ni.1736","article-title":"A protective function for interleukin 17A in T cell-mediated intestinal inflammation","volume":"10","author":"O\u2019Connor","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0110","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl. Recept. Signal."},{"key":"10.1016\/j.tips.2014.07.006_bib0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat","volume":"9","author":"Manel","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0120","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/ni1539","article-title":"TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology","volume":"8","author":"McGeachy","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni.2416","article-title":"Induction and molecular signature of pathogenic T(H)17 cells","volume":"13","author":"Lee","year":"2012","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/ni.2027","article-title":"ROR\u03b3t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation","volume":"12","author":"Codarri","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0135","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"El-Behi","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0140","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.tem.2012.05.012","article-title":"Action of RORs and their ligands in (patho)physiology","volume":"23","author":"Solt","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.tips.2014.07.006_bib0145","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nature09978","article-title":"Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR\u03b3t activity","volume":"472","author":"Huh","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tips.2014.07.006_bib0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","article-title":"The benzenesulfoamide T0901317 [N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethy l]phenyl]-benzenesulfonamide] is a novel retinoic acid receptor-related orphan receptor-alpha\/gamma inverse agonist","volume":"77","author":"Kumar","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2014.07.006_bib0155","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nature10075","article-title":"Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand","volume":"472","author":"Solt","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.tips.2014.07.006_bib0160","doi-asserted-by":"crossref","first-page":"22707","DOI":"10.1074\/jbc.C111.250407","article-title":"Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein","volume":"286","author":"Xu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2014.07.006_bib0165","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.4049\/jimmunol.1302190","article-title":"Pharmacologic inhibition of ROR\u03b3t regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo","volume":"192","author":"Skepner","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0170","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.autrev.2012.02.022","article-title":"Effective treatment of rat adjuvant-induced arthritis by celastrol","volume":"11","author":"Cascao","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.tips.2014.07.006_bib0175","doi-asserted-by":"crossref","first-page":"31409","DOI":"10.1074\/jbc.M111.254003","article-title":"Structural basis of digoxin that antagonizes RORgamma t receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production","volume":"286","author":"Fujita-Sato","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2014.07.006_bib0180","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2014.04.004","article-title":"Chemical inhibition of the ROR\u03b3t-dependent transcriptional network in T helper 17 cells","volume":"40","author":"Xiao","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.tips.2014.07.006_bib0185","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/cb3002649","article-title":"Identification of a selective ROR\u03b3 ligand that suppresses TH17 cells and stimulates T regulatory cells","volume":"7","author":"Solt","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2014.07.006_bib0190","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1021\/cb200496y","article-title":"Identification of SR2211: a potent synthetic ROR\u03b3-selective modulator","volume":"7","author":"Kumar","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2014.07.006_bib0195","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/art.38272","article-title":"Pharmacologic repression of retinoic acid receptor-related orphan nuclear receptor gamma is therapeutic in the collagen-induced arthritis experimental model","volume":"66","author":"Chang","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.tips.2014.07.006_bib0200","doi-asserted-by":"crossref","DOI":"10.1021\/jm401901d","article-title":"Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc)","volume":"57","author":"Fauber","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2014.07.006_bib0205","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0210","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.tips.2014.07.006_bib0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.tips.2014.07.006_bib0220","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3899\/jrheum.080458","article-title":"Association of interleukin 23 receptor variants with psoriatic arthritis","volume":"36","author":"Rahman","year":"2009","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.tips.2014.07.006_bib0225","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.tips.2014.07.006_bib0230","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.23389","article-title":"Association of interleukin-23 receptor variants with ankylosing spondylitis","volume":"58","author":"Rahman","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tips.2014.07.006_bib0235","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1128\/IAI.05242-11","article-title":"Role of interleukin-23 (IL-23) receptor signaling for IL-17 responses in human Lyme disease","volume":"79","author":"Oosting","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tips.2014.07.006_bib0240","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/ng.2007.17","article-title":"Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants","volume":"39","author":"Burton","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2014.07.006_bib0245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jneuroim.2011.12.004","article-title":"Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients","volume":"244","author":"Wen","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0250","doi-asserted-by":"crossref","first-page":"R215","DOI":"10.1186\/ar3194","article-title":"Increased interleukin-23 receptor(+) T cells in peripheral blood mononuclear cells of patients with systemic lupus erythematosus","volume":"12","author":"Puwipirom","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.tips.2014.07.006_bib0255","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1210\/jc.2007-2190","article-title":"Interleukin (IL)-23 receptor is a major susceptibility gene for Graves\u2019 ophthalmopathy: the IL-23\/T-helper 17 axis extends to thyroid autoimmunity","volume":"93","author":"Huber","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2014.07.006_bib0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/jc.2009-1719","article-title":"Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis","volume":"95","author":"Figueroa-Vega","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tips.2014.07.006_bib0265","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2014.07.006_bib0270","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: one cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.tips.2014.07.006_bib0275","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2014.07.006_bib0280","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2014.07.006_bib0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11595940-000000000-00000","article-title":"Briakinumab for the treatment of plaque psoriasis","volume":"26","author":"Traczewski","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.tips.2014.07.006_bib0290","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1056\/NEJMoa033402","article-title":"Anti-interleukin-12 antibody for active Crohn's disease","volume":"351","author":"Mannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2014.07.006_bib0295","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1053\/j.gastro.2008.07.014","article-title":"A randomized trial of Ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease","volume":"135","author":"Sandborn","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tips.2014.07.006_bib0300","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561471400128X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016561471400128X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T22:41:52Z","timestamp":1565736112000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016561471400128X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S016561471400128X"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2014.07.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting Th17 cells in autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2014.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}